We have demonstrated a novel role for RIP2 in the metastatic potential of multiple breast cancer cells with high RIP2 expression both in vitro and in vivo and shown that it is a target for drug treatment in cancer therapy. This evidence concerns the gene RIPK2 and breast cancer.